Promis Neurosciences Inc. · NASDAQ:PMN
Promis Neurosciences — Investor Presentation (2026)
16 slides from Promis Neurosciences's investor presentation, 2026
Slide 1: Targeting underlying causes of neurodegenerative diseases
Targeting underlying causes of neurodegenerative diseases
Slide 2: Forward Looking Statements Disclaimer
Forward Looking Statements Disclaimer This slide deck may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statem
Slide 3: Unique potential in areas of great unmet need
Unique potential in areas of great unmet need • Unique selectivity may create potential to address the unmet need for safer, more efficacious therapies • Data expected in 2026: Interim 6-month blinded Public (PMN:Nasdaq), based in Cambridge, MA analysis expected early Q3’26; top-line data expected e
Slide 4: EpiSelect computational platform allows for the generation of antibodies selective for toxic misfolded proteins
TM EpiSelect computational platform allows for the generation of antibodies selective for toxic misfolded proteins EpiSelect Proprietary Computational Modeling Approach Computational modeling Immunization with conformational Antibodies highly selective for toxic form epitope restricted to toxic form
Slide 5: Robust Pipeline Targeting Toxic Misfolded Proteins Across a Range of Neurodegenerative Diseases
Robust Pipeline Targeting Toxic Misfolded Proteins Across a Range of Neurodegenerative Diseases Product Disease Target Protein Discovery Preclinical Phase 1 Phase 2 Phase 3 Candidate Indication(s) PMN310* Amyloid-Beta Alzheimer’s Disease AN TIBO DY PMN267 TDP-43 ALS, FTD PMN442 Alpha-Synuclein PD, M
Slide 6: Lead Clinical Candidate PMN310 in Alzheimer's Disease
Lead Clinical Candidate PMN310 in Alzheimer’s Disease Selectivity for Toxic Aβ Oligomers
Slide 7: Toxic Aβ oligomers are minor in relative in-vivo abundance and constitute prime targets for Alzheimer's Disease
Toxic Aβ oligomers are minor in relative in-vivo abundance and constitute prime targets for Alzheimer’s Disease ILLUSTRATIVE RELATIVE ABUNDANCE OF Aβ SPECIES 1 Toxic Aβ Oligomers (AβOs) • As AβOs are the primary drivers of disease, Small, soluble clusters of Aβ Main driver of disease target concentr
Slide 8: Importance of selectivity for toxic amyloid-β oligomers
Importance of selectivity for toxic amyloid-β oligomers Monomers Oligomers Plaque Abundant Small, soluble clusters of Large, insoluble Play physiologic role Aβ – Main driver of disease aggregates of Aβ No efficacy or ARIA impact Limited efficacy Efficacy Safety from monomer binding Primary efficacy
Slide 9: PMN310 was the only mAb tested with undetectable plaque binding
PMN310 was the only mAb tested with undetectable plaque binding through fluorescent and chromogenic staining Isotype negative controls Test antibodies Plaque detection (no mAb) Amylo-Glo Staining with mAb (fluorescence) Staining with mAb (chromogenic) ARIA-E Rates ~25% ~21% Ph1 top dose ~13% ~35% St
Slide 10: Multi-Billion Dollar Sales Expectations for SoC Therapies Despite Limited Clinical Efficacy and Challenging Safety
Multi-Billion Dollar Sales Expectations for SoC Therapies Despite Limited Clinical Efficacy and Challenging Safety (ARIA) Modest Clinical Benefits Challenging Label Annual Sales Ests.(1) Adjusted Mean Change from Baseline in CDR-SB in Study 2 Black Box Warning: Amyloid related imaging ~$0.5B ~$3.2B
Slide 11: Phase 1a first-in-human single ascending dose (SAD) study met all objectives
Phase 1a first-in-human single ascending dose (SAD) study met all objectives and informed Phase 1b design and dosing Phase 1a SAD Trial Design (40 healthy volunteers, 5 dose levels) Key Findings Dose • PMN310 was generally well-tolerated in healthy PMN310 Placebo- 40 mg/kg (N = 6:2) volunteers acros
Slide 12: PRECISE-AD: PMN310 Phase 1b MAD Trial in Early AD Patients
PRECISE-AD: PMN310 Phase 1b MAD Trial in Early AD Patients 12-month Double-blind Treatment, Interim 6-month Data, Target N=100 Completers Fast Track Ph1b Placebo- 12-Month double-blinded treatment 6 Month Interim Data Controlled POC Study Designation (IV monthly dosing ) 1400 mg (20 mg/kg) Patient P
Slide 13: Upcoming Planned Interim Analysis Readout
Upcoming Planned Interim Analysis Readout Blinded 6-month Qualitative Analysis I Safety and Biomarker signal I Early Q3 ’26 Safety Profile to Date Blinded Biomarker Data Selected blinded data across key disease-relevant • Snapshot of ARIA incidence rate biomarkers. This may include: ▸ pTau 217 Disea
Slide 14: A catalyst-rich year: 2026 strategic priorities
A catalyst-rich year: 2026 strategic priorities Parallel workstreams converging on PMN310 Phase 3 readiness and broader pipeline advancement 2026 Q1 Q2 Q3 Q4 PRECISE-AD Phase 1b Phase 1b Execution PMN310 in early AD — execute + complete Subcutaneous PMN310 SC formulation + PK/PD Accelerated SC formu
Slide 15: ProMIS Neurosciences: Investment Summary
ProMIS Neurosciences: Investment Summary A New Standard for Disease-Modifying Alzheimer’s Therapy Unique Differentiation Near Term Catalysts Strong Clinical Profile Financial Strength • First & only therapy that • Blinded analysis expected • Robust ongoing Phase 1b • Recently closed $175M appears to
Slide 16: For further information, contact: info@promisneurosciences.com
For further information, contact: info@promisneurosciences.com NASDAQ: PMN